Finanzen von Abbott Laboratories (ABT)ABTAbbott Laboratories

Abbott Laboratories (ABT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Diabetes Care, accounting for 17.4% of total sales, equivalent to $2.19B. Other significant revenue streams include Core Laboratory and Key Emerging Markets. Understanding this composition is critical for investors evaluating how ABT navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Abbott Laboratories maintains a gross margin of 50.77%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 16.98%, while the net margin is 7.07%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ABT converts its operational activities into shareholder value.

In the context of the broader market, ABT competes directly with industry leaders such as DHR and ISRG. With a market capitalization of $177.61B, it holds a leading position in the sector. When comparing efficiency, ABT's gross margin of 50.77% stands against DHR's 59.34% and ISRG's 67.45%. Such benchmarking helps identify whether Abbott Laboratories is trading at a premium or discount relative to its financial performance.

Abbott's total revenue has shown a steady increase, with Q3 2026 revenue at $13.01 billion, up from $11.16 billion in Q2 2025. Gross margin remains strong at approximately 50.77% in Q3 2026, reflecting solid profitability despite recent challenges.